Associations of fibroblast growth factor 23 with urate metabolism in patients with chronic kidney disease

Teppei Sakoh, Masaru Nakayama, Takuya Tsuchihashi, Ryota Yoshitomi, Shigeru Tanaka, Eisuke Katafuchi, Akiko Fukui, Yui Shikuwa, Naohiko Anzai, Takanari Kitazono, Kazuhiko Tsuruya

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective In patients with preserved kidney function, a positive association of fibroblast growth factor 23 (FGF23) with serum uric acid (SUA) has been reported; however, the relationship in overall chronic kidney disease (CKD) patients has not been investigated. No report has examined the relationship between FGF23 and uric acid clearance (CUA). The aim of the present study was to determine whether FGF23 is independently associated with urate metabolism in patients with CKD stages 1–5. Materials and methods In this cross-sectional study, 537 CKD patients were enrolled. SUA, CUA, FGF23, parathyroid hormone (PTH), and 1,25-dihydroxyvitamin D (1,25(OH)2D) were measured. Multivariable linear regression analysis was applied to determine independent factors associated with SUA or CUA. Results In all patients, both SUA and CUA were independently associated with male sex, use of diuretics, use of uric acid-lowering agents, estimated glomerular filtration rate, and log FGF23 (β = 0.29, P < 0.01 for SUA; β = − 0.11, P < 0.01 for CUA), but not with log PTH or log 1,25(OH)2D. Dyslipidemia and diabetes were also independent factors for SUA and CUA, respectively. In multivariable analyses by sex, log FGF23 was associated with SUA in both sexes (β = 0.32, P < 0.01 in males vs. β = 0.20, P = 0.02 in females). Conversely, log FGF23 was independently associated with CUA in males (β = − 0.15, P < 0.01), but not in females (β = − 0.09, P = 0.17). Conclusions FGF23 was independently associated with urate metabolism in this population of CKD patients. FGF23 might also have a stronger association with urate metabolism in males compared with females.

Original languageEnglish
Pages (from-to)1498-1507
Number of pages10
JournalMetabolism: Clinical and Experimental
Volume65
Issue number10
DOIs
Publication statusPublished - Oct 1 2016

Fingerprint

Uric Acid
Chronic Renal Insufficiency
Serum
Parathyroid Hormone
fibroblast growth factor 23
Dyslipidemias
Glomerular Filtration Rate
Diuretics
Linear Models
Cross-Sectional Studies
Regression Analysis
Kidney

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Associations of fibroblast growth factor 23 with urate metabolism in patients with chronic kidney disease. / Sakoh, Teppei; Nakayama, Masaru; Tsuchihashi, Takuya; Yoshitomi, Ryota; Tanaka, Shigeru; Katafuchi, Eisuke; Fukui, Akiko; Shikuwa, Yui; Anzai, Naohiko; Kitazono, Takanari; Tsuruya, Kazuhiko.

In: Metabolism: Clinical and Experimental, Vol. 65, No. 10, 01.10.2016, p. 1498-1507.

Research output: Contribution to journalArticle

Sakoh, T, Nakayama, M, Tsuchihashi, T, Yoshitomi, R, Tanaka, S, Katafuchi, E, Fukui, A, Shikuwa, Y, Anzai, N, Kitazono, T & Tsuruya, K 2016, 'Associations of fibroblast growth factor 23 with urate metabolism in patients with chronic kidney disease', Metabolism: Clinical and Experimental, vol. 65, no. 10, pp. 1498-1507. https://doi.org/10.1016/j.metabol.2016.07.005
Sakoh, Teppei ; Nakayama, Masaru ; Tsuchihashi, Takuya ; Yoshitomi, Ryota ; Tanaka, Shigeru ; Katafuchi, Eisuke ; Fukui, Akiko ; Shikuwa, Yui ; Anzai, Naohiko ; Kitazono, Takanari ; Tsuruya, Kazuhiko. / Associations of fibroblast growth factor 23 with urate metabolism in patients with chronic kidney disease. In: Metabolism: Clinical and Experimental. 2016 ; Vol. 65, No. 10. pp. 1498-1507.
@article{a0fb1db9ce7c42b38d954db9a9c15898,
title = "Associations of fibroblast growth factor 23 with urate metabolism in patients with chronic kidney disease",
abstract = "Objective In patients with preserved kidney function, a positive association of fibroblast growth factor 23 (FGF23) with serum uric acid (SUA) has been reported; however, the relationship in overall chronic kidney disease (CKD) patients has not been investigated. No report has examined the relationship between FGF23 and uric acid clearance (CUA). The aim of the present study was to determine whether FGF23 is independently associated with urate metabolism in patients with CKD stages 1–5. Materials and methods In this cross-sectional study, 537 CKD patients were enrolled. SUA, CUA, FGF23, parathyroid hormone (PTH), and 1,25-dihydroxyvitamin D (1,25(OH)2D) were measured. Multivariable linear regression analysis was applied to determine independent factors associated with SUA or CUA. Results In all patients, both SUA and CUA were independently associated with male sex, use of diuretics, use of uric acid-lowering agents, estimated glomerular filtration rate, and log FGF23 (β = 0.29, P < 0.01 for SUA; β = − 0.11, P < 0.01 for CUA), but not with log PTH or log 1,25(OH)2D. Dyslipidemia and diabetes were also independent factors for SUA and CUA, respectively. In multivariable analyses by sex, log FGF23 was associated with SUA in both sexes (β = 0.32, P < 0.01 in males vs. β = 0.20, P = 0.02 in females). Conversely, log FGF23 was independently associated with CUA in males (β = − 0.15, P < 0.01), but not in females (β = − 0.09, P = 0.17). Conclusions FGF23 was independently associated with urate metabolism in this population of CKD patients. FGF23 might also have a stronger association with urate metabolism in males compared with females.",
author = "Teppei Sakoh and Masaru Nakayama and Takuya Tsuchihashi and Ryota Yoshitomi and Shigeru Tanaka and Eisuke Katafuchi and Akiko Fukui and Yui Shikuwa and Naohiko Anzai and Takanari Kitazono and Kazuhiko Tsuruya",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.metabol.2016.07.005",
language = "English",
volume = "65",
pages = "1498--1507",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - Associations of fibroblast growth factor 23 with urate metabolism in patients with chronic kidney disease

AU - Sakoh, Teppei

AU - Nakayama, Masaru

AU - Tsuchihashi, Takuya

AU - Yoshitomi, Ryota

AU - Tanaka, Shigeru

AU - Katafuchi, Eisuke

AU - Fukui, Akiko

AU - Shikuwa, Yui

AU - Anzai, Naohiko

AU - Kitazono, Takanari

AU - Tsuruya, Kazuhiko

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Objective In patients with preserved kidney function, a positive association of fibroblast growth factor 23 (FGF23) with serum uric acid (SUA) has been reported; however, the relationship in overall chronic kidney disease (CKD) patients has not been investigated. No report has examined the relationship between FGF23 and uric acid clearance (CUA). The aim of the present study was to determine whether FGF23 is independently associated with urate metabolism in patients with CKD stages 1–5. Materials and methods In this cross-sectional study, 537 CKD patients were enrolled. SUA, CUA, FGF23, parathyroid hormone (PTH), and 1,25-dihydroxyvitamin D (1,25(OH)2D) were measured. Multivariable linear regression analysis was applied to determine independent factors associated with SUA or CUA. Results In all patients, both SUA and CUA were independently associated with male sex, use of diuretics, use of uric acid-lowering agents, estimated glomerular filtration rate, and log FGF23 (β = 0.29, P < 0.01 for SUA; β = − 0.11, P < 0.01 for CUA), but not with log PTH or log 1,25(OH)2D. Dyslipidemia and diabetes were also independent factors for SUA and CUA, respectively. In multivariable analyses by sex, log FGF23 was associated with SUA in both sexes (β = 0.32, P < 0.01 in males vs. β = 0.20, P = 0.02 in females). Conversely, log FGF23 was independently associated with CUA in males (β = − 0.15, P < 0.01), but not in females (β = − 0.09, P = 0.17). Conclusions FGF23 was independently associated with urate metabolism in this population of CKD patients. FGF23 might also have a stronger association with urate metabolism in males compared with females.

AB - Objective In patients with preserved kidney function, a positive association of fibroblast growth factor 23 (FGF23) with serum uric acid (SUA) has been reported; however, the relationship in overall chronic kidney disease (CKD) patients has not been investigated. No report has examined the relationship between FGF23 and uric acid clearance (CUA). The aim of the present study was to determine whether FGF23 is independently associated with urate metabolism in patients with CKD stages 1–5. Materials and methods In this cross-sectional study, 537 CKD patients were enrolled. SUA, CUA, FGF23, parathyroid hormone (PTH), and 1,25-dihydroxyvitamin D (1,25(OH)2D) were measured. Multivariable linear regression analysis was applied to determine independent factors associated with SUA or CUA. Results In all patients, both SUA and CUA were independently associated with male sex, use of diuretics, use of uric acid-lowering agents, estimated glomerular filtration rate, and log FGF23 (β = 0.29, P < 0.01 for SUA; β = − 0.11, P < 0.01 for CUA), but not with log PTH or log 1,25(OH)2D. Dyslipidemia and diabetes were also independent factors for SUA and CUA, respectively. In multivariable analyses by sex, log FGF23 was associated with SUA in both sexes (β = 0.32, P < 0.01 in males vs. β = 0.20, P = 0.02 in females). Conversely, log FGF23 was independently associated with CUA in males (β = − 0.15, P < 0.01), but not in females (β = − 0.09, P = 0.17). Conclusions FGF23 was independently associated with urate metabolism in this population of CKD patients. FGF23 might also have a stronger association with urate metabolism in males compared with females.

UR - http://www.scopus.com/inward/record.url?scp=84979889688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979889688&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2016.07.005

DO - 10.1016/j.metabol.2016.07.005

M3 - Article

C2 - 27621185

AN - SCOPUS:84979889688

VL - 65

SP - 1498

EP - 1507

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 10

ER -